logo
Plus   Neg
Share
Email

Affimed Posting Steep Loss After Halting Studies Of Cancer Drug

After gapping open sharply lower, shares of Affimed N.V. (AFMD) continue to see substantial weakness in afternoon trading on Tuesday. Affimed is currently down by 24.3 percent after hitting its lowest intraday level in over a month.

The initial sell-off by Affimed came after the biopharmaceutical company placed two clinical trials of its cancer treatment AFM11 on hold after one patient died and two others experienced life-threatening events.

Affimed said it will be working closely with the global health authorities, the Safety Monitoring Committees, and the studies' clinical investigators to review the events, carefully assess all of the data and determine next steps for the AFM11 program.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20... NetApp Inc. (NTAP) Wednesday reported a fourth-quarter profit that fell short of Wall Street estimates, as revenues slipped 3 percent. Shares of the company slipped 6% in extended trading session after its first-quarter outlook was also short of current expectations. Sunnyvale, California-based NetApp...
Follow RTT